The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
post
The Strategic Role of Regulatory Affairs in the Pharmaceutical Industry
Read More
post
The Real Cost of Uncertainty: Why On-Again, Off-Again Tariffs Hurt Biotech Supply Chains
Read More
post
Accelerating a Cytotoxic Peptide-Drug Conjugate to IND: A Medicinal Chemist’s Journey to IND with Syner-G BioPharma Group
Read More
post
Navigating Analytical Method Comparability and Equivalency Under ICH Q14: A New Era for Analytical Procedure Lifecycle Management
Read More
Let's move from science to success.
Let’s Talk